FIGURE 2.

Study population included 902 patients randomized to the treatment phase, with 55 patients in the MAP0004 treatment group and 56 patients in the placebo group discontinuing or withdrawing from the study because of the lack of a qualifying migraine, not receiving a dose of study medication, or lacking a follow-up assessment. In all, 10 patients in the MAP0004 treatment group and 10 patients in the placebo group were excluded from the subanalysis population because they did not report the time of their treatment. ITT = intent-to-treat.